Four methods for estimating hepatitis C incidence using extant testing data
PLOS One · 10.06.2026 · 21 (6) · e0335115
DOI: 10.1371/journal.pone.0335115 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 10.06.2026. Verfasst von William J McFarlane und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Hepatitis C. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Queen’s Fund for Scholarly work.
Abstract (Originalsprache)
Background
Accurate estimation of hepatitis C (HCV) incidence is crucial for measuring progress towards HCV elimination targets set by the World Health Organization (WHO). Extant HCV antibody (Ab) and RNA test results are widely used to estimate HCV incidence, but the impact of cohort specification and case definition on validity and generalizability is poorly understood.
Methods
Using databases linked at ICES – a repository of administrative health data for Ontario residents – we constructed a cohort of 15.8 million Ontarians aged 18–80 between 1999 and 2018 to estimate annual HCV incidence using four methods. The population-based method calculated HCV incidence as the number of new HCV diagnoses each year divided by annual population size estimates, while Poisson regression was used in the other three incidence estimation methods: the test-negative method defined eligibility at first negative test; the RNA-based method prioritized specificity by requiring RNA+ tests; and the antibody-inclusive method prioritized sensitivity by including all Ab+ tests.
Results
Distinct patterns of HCV incidence were found across the estimation methods: the RNA-based estimates were lowest and fluctuated around 30 cases per 100,000 person-years, while population-based and antibody-inclusive estimates were 1.5-fold higher, and test-negative estimates were 7.9-fold higher. Population-based estimates were sensitive to changes in the HCV case definition used in Ontario from 1999–2018. The test-negative cohort had a high prevalence of human immunodeficiency virus (HIV) and substance use disorder, limiting generalizability of HCV incidence estimates. RNA-based estimates likely underestimated HCV incidence because 22% of Ab+ tests were unconfirmed by RNA testing, while antibody-inclusive estimates likely overestimated HCV incidence by assuming all unconfirmed Ab+ tests were true cases.
Conclusion
These new findings illustrate the influence of cohort definition and HCV case definition when estimating HCV incidence using extant testing data, which will support accurate measurement of progress towards WHO HCV elimination goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
- ICES Queen's, Kingston, Ontario, Canada.
- Department of Medicine, Queen's University, Kingston, Ontario, Canada.
- Department of Surgery, Queen's University, Kingston, Ontario, Canada.
ORCID-Profile: William J McFarlane, Jennifer A Flemming
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Queen’s Fund for Scholarly work
Zitieren
APA
McFarlane, W. J., Flemming, J. A., Brogly, S. B., & Peng, Y. (2026). Four methods for estimating hepatitis C incidence using extant testing data. PLOS One, 21(6), e0335115. https://doi.org/10.1371/journal.pone.0335115
Vancouver
McFarlane WJ, Flemming JA, Brogly SB, Peng Y. Four methods for estimating hepatitis C incidence using extant testing data. PLOS One. 2026;21(6):e0335115. doi:10.1371/journal.pone.0335115
BibTeX
@article{McFarlane2026,
author = {McFarlane, William J and Flemming, Jennifer A and Brogly, Susan B and Peng, Yingwei},
title = {Four methods for estimating hepatitis C incidence using extant testing data},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0335115},
doi = {10.1371/journal.pone.0335115}
}
EUVIMED